Then, for the next 52-weeks, some patients were randomized to continue the season (AKA continue tirzepatide), or to turn the TV off (placebo)
But for many people, weight loss is far more complicated than "eat less, move more." Here's what we hear from patients before they come to us: The weight loss plateau is real and demoralizing You were making progress, and then everything just stopped
Start now. Daniell feels that her journey to return to healthy habits makes sense based on her past
Key questions remain around access, long-term use, and how healthcare can manage these costs while delivering downstream value
[1] [4] The only FDA-approved forms of tirzepatide are the pre-filled, single-dose injection pens marketed as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management)
Like Victoza, it has a sister drug, Wegovy, which also has semaglutide as its active ingredient